Recent studies addressing issues concerning the administration of Trojan fusion proteins directly into the brain [51], [52], suggest the realistic possibility of using our Trojan fusion Rac1 mutants as a potential therapeutic approach to modulate neuron survival and axonal regeneration in neurodegenerative diseases. The gene discussed is RAC1; the disease is neurodegenerative disease.